Here’s a brief look at 6 medications for rheumatologic disorders that were newly approved in the second half of 2018.
Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis Gets FDA Nod
The approval is based on data from two randomized, sham injection-controlled, double-masked phase 3 clinical trials with patient follow-up for 3 years.
Adalimumab for the treatment of noninfectious uveitis has advantages over no treatment or conventional treatment with steroid therapy.
In this story, we revisit the clinical trials that led to the approval of adalimumab for uveitis.
The tumor necrosis factor α antagonist infliximab has been used for treating patients with uveitis resistant to corticosteroids.